The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Fri, 20th Mar 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

InterContinental Hotels Group, up 11%. The Holiday Inn and Crowne Plaza owner said demand is currently at the lowest level it has ever seen. To combat this, IHG is hoping to save about USD150 million through salary cuts, including "substantial" reduction in salary and incentives from its board and executive committee. Also, IHG will pull its final dividend of 85.9 US cents - saving about USD150 million - and said it will delay any further dividends until "visibility has improved". The hotel owner will also delay renovations and relax brand standards. Turning to trading, IHG said its global revenue per available room was down 6% in January and February, with a flat performance in the US being offset by a catastrophic drop in Greater China. In February, RevPAR in Greater China was down 90% year on year.

----------

Carnival, up 5.2%. The cruise operator said revenue for the first quarter increased 2.1% to USD4.8 billion from USD4.7 billion a year ago. However, Carnival swung to a first-quarter loss, with earnings dented by disruption due to the early days of the current Covid-19 pandemic. The company recorded a GAAP net loss of USD781 million, or USD1.14 per share, for the quarter ended February 29. This compares to net income of USD336 million, or earnings per share of USD0.48, for the first quarter a year ago. The impact of Covid-19 on the first quarter's net loss was around USD0.23 per share, the firm said, taking into account cancelled voyages and disruptions. Carnival said Covid-19 will have a "material negative impact" on its financial results and liquidity.

----------

FTSE 250 - WINNERS

----------

Future, up 30%. The media company said declines in its travel magazine portfolio have been offset by its grocery titles, resulting in "strong" digital audience numbers. "The period started well with exceptionally strong digital audience numbers with the resultant beneficial flow through to eCommerce and digital advertising," Future said. As a result, the company expects its results for the six months to the end of March to be in line with internal expectations. "The recent weeks have been unprecedented. However, our business has continued to trade robustly, with the diversified strategy working well. As of today, we have seen limited impact on our digital revenues," Future said. Despite the "robust" trading, Future said it is implementing some profit protection measures.

----------

JD Wetherspoon, up 27%. The pub chain operator reported a rise in profit and revenue in the first half of its financial year, but has cancelled its dividend due to the uncertainty surrounding the Covid-19 outbreak. In the 26 weeks to January 26, Wetherspoon's recorded pretax profit of GBP57.9 million, up 15% from the GBP50.3 million seen in the same period the year before. Revenue was 4.9% higher year-on-year at GBP933.0 million from GBP889.6 million. Like-for-like sales in the first half of the financial year were 5.0% higher. Like-for-like bar sales increased by 4.2%, food sales by 5.6% and fruit/slot machines by 20%. Like-for-like hotel room sales decreased by 1.3%, however. Bar sales were 60% of total sales, Wetherspoons noted. Despite the strong performance, the bar owner has cancelled its interim dividend - owing to the uncertainty caused by the spread of Covid-19.

----------

FTSE 250 - LOSERS

----------

Inchcape, down 3.1%. The automotive retailer said it will suspend its share buyback programme due to uncertainty arising from the Covid-19 outbreak. Inchcape has completed around GBP25 million of the GBP150 million repurchase programme but will serve notice to its brokers to terminate the buyback effective from next Tuesday. "Inchcape has a strong balance sheet and remains committed to its disciplined capital allocation policy, but the board believes this is the right decision at this time," the company said. As at the end of 2019, the company had cash of GBP423.0 million with total assets valued at GBP4.46 billion.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Faron Pharma, up 16%. The Finnish drug discovery company said its assets increased to EUR1.6 million in 2019 compared to just EUR400,000 reported a year earlier. As at December 31, the company said it had cash balances of EUR7.1 million compared to EUR4.1 million the year before. As a result, pretax loss narrowed to EUR13.3 million from EUR20.1 million year-on-year. The company did not generate any revenue during the year as it is currently focused on the development of Clevegen, a novel cancer immunotherapy.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Christie Group, down 5.5%. The financial services provider said it expects its 2019 results to be in line with expectations. The company said it has benefited from the profitable sale of an office building, as mentioned in our Interim results statement. However, Christie noted that its business - which operate in the hospitality, retail, medical and educational fields - took a hit from the Covid-19. This is primarily as a result of having limited access to certain of its clients' premises. "It is not currently possible to quantify the full effect of Covid-19 related disruption on our business for 2020 or beyond," said Christie in its statement Friday.

----------

Tracsis, down 1.7%. The traffic data provider said it is not possible to accurately quantify the impact on the second-half trading and therefore full year expectations amid rapidly changing situation with coronavirus. Tracsis said it expects the Rail Technology & Services division to have resilience as it derives most of its income from highly recurring product sales. However, parts of the Traffic & Data Services division are forecast to be hurt by Covid-19. In particular, the company's events businesses SEP and CTM both derive a significant amount of revenue from major UK based outdoor events, and in recent days Tracsis said it has been notified by some major clients that events scheduled for this summer will either be cancelled or postponed to the autumn. Tracsis said it expects further events to be cancelled or postponed in due course.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Nov 2023 11:03

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Read more
6 Nov 2023 10:31

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).

Read more
30 Oct 2023 15:56

TRADING UPDATES: Bezant optimistic after Hope & Gorob estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
11 Oct 2023 14:53

Faron Pharmaceuticals upbeat on latest data in blood cancer trials

(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.

Read more
11 Oct 2023 14:01

IN BRIEF: Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Read more
21 Sep 2023 14:45

Faron Pharmaceuticals names interim chief medical officer

(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on 22 September, with Dr Berns operating from the UK.

Read more
21 Sep 2023 12:12

TRADING UPDATES: Faron appoints Birge Berns as interim medical officer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Sep 2023 15:46

UK shareholder meetings calendar - next 7 days

Monday 18 September 
Baillie Gifford US Growth Trust PLCAGM
Inteliqo LtdAGM
LendInvest PLCAGM
Rosslyn Data Technologies PLCGM re fundraise
Tuesday 19 September 
Africa Opportunity Fund LtdAGM
Aston Martin Lagonda Global Holdings PLCGM re supply arrangement with Lucid Group Inc
Augmentum Fintech PLCAGM
Beacon Rise Holdings PLCAGM
Begbies Traynor Group PLCAGM
Chill Brands Group PLCAGM
DP Aircraft I LtdAGM
Great Southern Copper PLCAGM
Manolete Partners PLCAGM
Moonpig Group PLCAGM
Oxford Instruments PLCAGM
ProCook Group PLCAGM
SRT Marine Systems PLCAGM
Unicorn Mineral Resources PLCAGM
Wednesday 20 September 
Accsys Technologies PLCAGM
Frasers Group PLCAGM
Games Workshop Group PLCAGM
Hidong Estate PLCAGM
IG Group Holdings PLCAGM
Ilika PLCAGM
Nippon Active Value Fund PLCGM re assets rollover
Quiz PLCAGM
Seed Innovations LtdAGM
STS Global Income & Growth Trust PLCAGM
Thursday 21 September 
Ascent Resources PLCGM re audited annual accounts
Intercede Group PLCAGM
Kore Potash PLCGM re capital raise
Liontrust Asset Management PLCAGM
Mercia Asset Management PLCAGM
Molecular Energies PLCAGM
Oberon Investments Group PLCAGM
Pelatro PLCGM re AIM cancellation
Sosandar PLCAGM
Thruvision Group PLCAGM
Trakm8 Holdings PLCAGM
Van Elle Holdings PLCAGM
Friday 22 September 
Argos Resources LtdGM re members voluntary liquidation
B&M European Value Retail SAGM re appointing Lasry as director
Faron Pharmaceuticals LtdEGM re election of new board members
Stranger Holdings PLCAGM
SysGroup PLCAGM
TI Fluid Systems PLCGM re waiver resolution
Odyssean Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
29 Aug 2023 10:23

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
29 Aug 2023 10:15

Faron shares surge on FDA drug designation; loss widens on costs

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jul 2023 10:27

Faron Pharmaceuticals sees positive data from phase 1 BEXMAB trial

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data.

Read more
29 Jun 2023 18:55

TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
9 Jun 2023 14:34

TRADING UPDATES: Medica shareholders back takeover; Arecor optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.